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The effect of platelet-activating factor (PAF) on polyphosphoinositide metabolism and 45Ca2+ et%ux was 
examined in a vascular smooth muscle cell line (A,r,). PAP stimulated a rapid but transient production 
of inositol trisphosphate and inositol bisphosphate which, in the presence of lithium, resulted in an accumu- 
lation of inositol monophosphate. In addition, PAF induced a rapid efflux of 45Ca2+ from preloaded cells, 
an effect which was concentration-dependent. These data suggest hat PAF mobilises intracellutar Caz+ via 
the production of inositol trisphosphate. 
Ca2’ Inositolphosphate Plateiet-activating factor (Rat smooth muscle) 
1. INTRODUCTION 
PlateIet-activating factor (PAF, AGEPC, APRL, 
Paf-acether) is an ether-linked phospholipid im- 
plicated in a diverse range of pathological condi- 
tions including asthma [l], circulatory disorders 
[2] and inflammation [3f. PAF was originally 
described as a potent plateiet stimulant inducing 
shape change, granule reiease and aggregation at 
concentration as low as lo-l2 M [4-61. However, 
recent studies indicate that PAF has potent biolo- 
gical activity in a number of other cell types in 
vitro and in vivo (reviews [3,7]) although little is 
known about the biochemical basis for such activi- 
ty. It is, however, recognized that PAF has highly 
specific effects which are often dependent on CaZf 
and can be associated with changes in phospho- 
lipids [5,7-91. Here, we have evaluated the bio- 
chemical changes induced by PAF in a smooth 
muscle cell line orginating from rat aorta. 
2. MATERIALS AND METHODS 
2.1. Miateriuls 
[3H]Inositol and 4rCa2+ were obtained from 
Amersham Internationai, England. PAF was pur- 
chased from Bachem, Bubendorf, Switzerland. 
PAF antagonist (CV 3988) was a kind gift of 
Takeda, Japan. All other chemicals used were of 
the highest grade purity available. 
2.2. Cell culture 
The rat aortic smooth muscle cell line A7rj was 
obtained from the American Type Tissue Culture 
Collection, Rockville, MD. The cells were tryp- 
sinised and subcultured at a density of 7000 cells/ 
cm2 in dishes of 16 mm diameter. Experiments 
were carried out on confluent monolayers of cells 
between the 7 and 14th day after plating. Measure- 
ment of inositol phosphates and 4sCa2+ efflux was 
carried out as in [IO]. 
3. RESULTS 
In smooth muscle cells which had been preIabeIl- 
ed to equihbrium with [3H]inositol, stimulation 
with PAF (IO-’ M) resulted in the formation of 
InsPr, InsP2 and InsP3. InsP3 production reached 
a peak level at approx. 30 s and declined to control 
levels within 5 min (fig.la). Similarly, production 
of InsP2 was transient with m~mum levels occur- 
ring between I and 3 min, thereafter deciining 
towards control levels. Formation of InsPr pro- 
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Fig, 1. Effect of PAF on inositol lipid metabolism in 
vascular smooth muscle ceils. (a) Kinetics of PAF- 
mediated InsPi (e---o), InsPz (0---0) and InsP3 
(a) production in ceIIs prelabelled with (31-IlinositoI 
(n = 7). (b) Concentration-response r lationship of PAF- 
mediated InsP, production (n = 4). 
ceeded at a much slower rate than that of InsP3 but 
continued increasing up to 5 min, the latest time 
point measured. Accumulation of inositol phos- 
phates as InsPI following receptor stimulation in 
the presence of lithium is a sensitive assay of activi- 
ty of Ca’+ -mobilising hormones [I 11. Fig. 1 b shows 
the concentration dependence of PAF-induced 
InsPi accumulation measured at 10 min in the 
presence of lithium. The concentration of PAF re- 
quired to provoke half-m~imal InsPl production 
was 5 x lo-‘* M. 
Fig.2a shows the kinetics of PAF-induced 45Ca2+ 
efflux from preloaded cells. PAF (lo-’ M) was 
,: B 0 1,. t 12 11 10 9 8 7 6 
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Fig.2. The effect of PAF on 4sCa2+ efflux in vascular 
smooth muscle cells. (a) Kinetics of the PAF-stimulated 
4sCaz+ efflux in preloaded cells (n = 3). (b) Concentra- 
tion-response curve of PAF-stimulated 4SCa2t effIux 
(n=5). 
added after IO min of efflux in PSS and the 
45CaZ+remaining i  the cells was measured after an 
additional 10 min. PAF reduced the 45Ca2+ remain- 
ing in the cells to 50% of that in the control, in- 
dicating a rapid stimulation of efflux. Using the 
same protocol, the EC50 value for PAF-induced 
45CaZ+ efflux was 4x IO-” M, with efflux being 
essentially complete at 10e9 M (fig.2b). 
Incubation of smooth muscle cells with the PAF 
antagonist CV 3988 (low5 M) or indomethacin 
(lob6 M), a cyclooxygenase inhibitor, affected 
neither InsPI levels nor basal Cai+ efflux. How- 
ever, CV 3988 completely abolished those stimulat- 
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Table 1 
Effects of various agents on basal and PAF-stimulated 
InsPi accumulation and 45CaZ+ efflux 
InsPi 45ca2+ 
Control 100 + 2 100 * 3 
PAF 223 Y!Z 9* 59 + 3* 
CV 3988 (lo-’ M) 108 f 6 98 + 7 
PAF + CV 3988 (1O-6 M) 190 + 7* 68 f 6* 
PAF + CV 3988 (lo-’ M) 101 f 3 101 + 4 
Indomethacin 97 f 4 98 + 8 
PAF + indomethacin 221 f 10* 59 + 1* 
Lyso-PAF (lo-’ M) 95 f 7 99 + 4 
The concentrations of PAF used were lo-’ M and 
lo-’ M for InsPi accumulation and 45CaZ+ efflux, 
respectively; the concentration of indomethacin used 
was lOO-times that of PAF. Results are presented as % 
of the control values (mean f SE, n = 3-5). The 45Ca2+ 
efflux data are presented as % 4sCa2+ remaining in the 
cells. Significance levels, as compared to control values, 
were assessed by Student’s t-test; *p<O.OOl. CV 3988; 
rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl- 
2-thiazolioethyl phosphate 
ed by PAF whereas indomethacin was ineffective 
(table 1). 
4. DISCUSSION 
Binding sites for PAF have been shown to be 
present on a number of cell types including plate- 
lets [12-141, neutrophils [15,16], guinea pig smooth 
muscle membranes [12] and lung tissue [ 171, sug- 
gesting that PAF exerts its effects via a specific ex- 
tracellular receptor. Investigation of the post- 
receptor events intrinsic to PAF action has been 
carried out mainly in platelets where PAF can 
elevate the intracellular calcium level, [Ca’+]i, 
although it stimulates shape change even when 
[Ca*+]i is suppressed [18]. PAF also stimulates a 
rapid degradation of PtdInsPz and production of 
phosphatidic acid [8,19-221. Such results indicate 
that PAF induces a phospholipase C-mediated 
breakdown of PtdInsP2, which is thought to be the 
initial event in the widely documented transducing 
mechanism of hormones and neurotransmitters 
which utilise Ca2+ as a second messenger [23,24]. 
Hydrolysis of PtdInsP2 yields 2 products, InsPJ, 
thought to serve as a second messenger for the 
mobilization of [Ca*+]i [25-271 and 1 ,d-diacyl- 
glycerol which activates protein kinase C, which in 
platelets is considered to be a necessary step for 
shape change and aggregation [9,28]. In this study 
we demonstrate that in smooth muscle cells, PAF 
stimulates the production of InsP3 and subsequent 
release of 45Ca2+. 
In A7r5 cells PAF stimulates production of 
inositol phosphates with a kinetic pattern similar 
to those reported in other cultured cells stimulated 
with various Ca*+ -mobilising ligands [ 10,291. Pro- 
duction of InsP3 is more rapid than that of InsP2 a 
or InsPi, but also declines rapidly. InsPi produc- 
tion exhibits a much slower time course but due to 
the presence of lithium, which inhibits inositol-l- 
phosphatase, continues over a longer period of 
time [l 11. Thus, as described for other systems 
[10,30-331, InsP3 derived from PtdInsP2 break- 
down is rapidly degraded by phosphomonoesterases 
to InsPi via InsP2. The production of InsP3 is suf- 
ficiently rapid to account for the equally rapid ef- 
flux of Ca*+, indicating that, as previously de- 
scribed in other cell systems, InsP3 could be 
responsible for intracellular Ca*+ release. 
The concentration of PAF required to provoke 
half-maximal accumulation of InsPi was 5 x 
lo-” M whereas half-maximal efflux of Ca*+ re- 
quired a lower concentration of PAF, 4 x 10-i’ M. 
Thus, maximal Ca*+ efflux will occur when in- 
ositol lipid hydrolysis is only partially activated. 
This has been observed in other cells [34] and has 
been explained as a receptor reserve. Under these 
conditions, any reaction essential to receptor- 
response coupling, e.g. activation of adenylate 
cyclase or PtdInsPz depletion, may only be sub- 
maximally activated even though a full physiolo- 
gical effect is observed [35]. 
A curious feature of PAF antagonists is they are 
required in high concentrations, up to lOOO-fold 
greater than the PAF concentration. For example, 
complete inhibition of PAF (3 x lo-* M)-induced 
rabbit platelet aggregation by the synthetic PAF 
antagonist CV 3988 is achieved at 3 x 10m5 M [36]. 
Similarly in this study, lo-’ M CV 3988 was 
necessary to cause complete inhibition of the 
response elicited by IO-* M PAF in InsPi ac- 
cumulation and Ca*+ efflux. Nevertheless, the ex- 
perimental observations indicate that both PAF- 
mediated InsPi production and Ca*+ efflux are 
related events which are the consequence of the in- 
teraction of PAF with an extracellular eceptor. In 
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support of this are our findings that lyso-PAF is 
unable to mimic the action of PAF and indo- 
methacin is unable to inhibit the effects of PAF. 
In conclusion, our data support the concept that 
PAF interacts directly with a specific receptor on 
the smooth muscle cell. Hwang et al. [12] have 
shown specific binding sites for PAF on several 
tissues, including rabbit ileal smooth muscle mem- 
branes, with a dissocation constant in the nano- 
molar range. Our findings support the view that 
these sites are functional receptors, the stimulation 
of which results in phospholipase C-mediated 
degradation of PtdInsPz and the subsequent pro- 
duction of InsPJ and 1,Zdiacylglycerol. InsP3 has 
been reported to promote the release of Ca2+ from 
an intracellular store, probably the endoplasmic 
reticulum [25-271. This effect of PAF appears to 
be specific as it is blocked by a PAF antagonist, 
CV 3988. However, this may not be the sole 
mechanism involved in PAF stimulation. Further 
studies of the biochemical events in PAF stimula- 
tion may facilitate the elucidation of the role of 
PAF in many diverse pathological conditions. 
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